Novel pharmacological treatments for heart failure

Bibliography

• AMERICAN HEART ASSOCIATION: Heart and Stoke Statistics — 2003 Update. American Heart Association, Dallas, TX, USA (2002).
   Google Scholar
• LLOYD-JONES DM, LARSON MG, LEIF EP et al.: Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation (2002) 106:3068–3072.
   PubMed Web of Science ®Google Scholar
• PACKER M: The impossible task of developing a new treatment for heart failure.' Card. Fail. (2002) 8:193–196.
   PubMed Web of Science ®Google Scholar
• MEHRA MR, UBER PA, FRANCIS GS: Heart failure therapy at a crossroad: are there limits to the neurohormonal model? Ain. Coll. Cardiol (2003) 41:1606–1610.
   PubMed Web of Science ®Google Scholar
• KALRA PR, MOON JC, COATS AJ: Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int. J. Cardiol (2002) 85:195–197.
   Web of Science ®Google Scholar
• ABRAHAM WT: Enrasentan CooperativeRandomized Evaluation (ENCOR" American College of Cardiology 50th Annual Scientific Session, Atlanta, GA, USA (2001).
   Google Scholar
• ANAND I, LUSCHER TF: The EARTH trial. XXIV Congress of the European Society of Cardiology Berlin, Germany (2002).
   Google Scholar
• OMAPATRILAT CARDIOVASCULAR TREATMENT ASSESSMENT VERSUS ENALAPRIL (OCTAVE): To compare the efficacy and safety of omapatrilat against enalapril in the treatment of hypertension. American College of Cardiology 51st Annual Scientific Session, Atlanta, GA, USA (2002).
   Google Scholar
• PACKER M, CALIFF RM, KONSTAM MA et al.: Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation (2002) 106:920–926.
   PubMed Web of Science ®Google Scholar
• COATS AJ: Heart failure 99 - the MOXCON story. Int. J. Cardiol (1999) 71:109–111.
   PubMed Web of Science ®Google Scholar
• BETA-BLOCKER EVALUATION AND SURVIVAL TRIAL INVESTIGATORS: A trial of the beta-blocker bucindolol in patients with advanced heart failure. N Engl. J. Med. (2001) 344:1659–1667.
   PubMed Web of Science ®Google Scholar
• COHN JN, TOGNONI G, THE VALSARTAN HEART FAILURE TRIAL INVESTIGATORS: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl. I. Med. (2001) 345:1667–1675.
   PubMed Web of Science ®Google Scholar
• GRANGER CB, McMURRAY JJ, YUSUF S et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet (2003) 362:772–776.
   PubMed Web of Science ®Google Scholar
• McMURRAY JJ, OSTERGREN J, SWEDBERG K et al: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet (2003) 362:767–771.
   PubMed Web of Science ®Google Scholar
• PFEFFER MA, McMURRAY J, LEIZOROVICZ A et al.: Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am. Heart (2000) 140:727–734.
   PubMed Web of Science ®Google Scholar
• PITT B, REMME W, ZANNAD F et al:Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl. I. Med. (2003) 348:1309–1321.
   PubMed Web of Science ®Google Scholar
• PITT B, ZANNAD F, REMME WJ et al:The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl. J. Med. (1999) 341:709–717.
   PubMed Web of Science ®Google Scholar
• WEBER KT: Aldosterone in congestive heart failure. N Engl. I Med. (2001) 345:1689–1697.
   PubMed Web of Science ®Google Scholar
• ROCHA R, WILLIAMS GH: Rationale forthe use of aldosterone antagonists in congestive heart failure. Drugs (2002) 62:723–731.
   PubMed Web of Science ®Google Scholar
• KRUM H, NOLLY H, WORKMAN D et al: Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension (2002) 40:117–123.
   PubMed Web of Science ®Google Scholar
• WEINBERGER MH, RONIKER B, KRAUSE SL, WEISS RJ: Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am. J. Hypertens. (2002) 15:709–716.
   PubMed Web of Science ®Google Scholar
• TANG WH, VAGELOS RH, YEE YG et al: Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. I. Am. Coll. Cardiol. (2002) 39:70–78.
   PubMed Web of Science ®Google Scholar
• PITT B, REICHEK N, WILLENBROCK R et al: Effects of eplerenone, enalapril, and eplerenone/ enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation (2003) 108: 1831-1838.
   Google Scholar
• ZANNAD F, ALLA F, DOUSSET B, PEREZ A, PITT B: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). RALES Investigators. Circulation (2000) 102:2700–2706.
   PubMed Web of Science ®Google Scholar
• GRANDI AM, IMPERIALE D, SANTILLO R et al: Aldosterone antagonist improve diastolic function in essential hypertension. Hypertension (2002) 40:647–652.
   PubMed Web of Science ®Google Scholar
• GOLDSMITH SR: Congestive heart failure: potential role of arginine vasopressin antagonists in the therapy of heart failure. Congest. Heart Fail (2002) 8:251–256.
   PubMedGoogle Scholar
• YATSU T, TOMURA Y, TAHARA A: Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin VIA and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure. Eur. Pharmacol (1999) 376:239–246.
   PubMed Web of Science ®Google Scholar
• NAITOH M, SUZUKI H, MURAKAMI M: Effects of oral AVP receptor antagonists 0PC21268 and 0PC31260 on congestive heart failure in conscious dogs. km Physiol (1994) 267:H2245–H2254.
   Web of Science ®Google Scholar
• RUSSELL SD, SELARU P, PYNE DA et al.: Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin Antagonist in CHF patients undergoing Exercise) trial. Am. Heart J. (2003) 145:179–186.
   PubMed Web of Science ®Google Scholar
• GHEORGHIADE M, NIAZI I, OUYANG J et al: Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation (2003) 107:2690–2696.
   PubMed Web of Science ®Google Scholar
• GHEORGHIADE M, GATTIS WA, BARBAGELATA A et al.: Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. Am. Heart J. (2003) 145:S51–S54.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB SS: Renal effects of adenosine Al-receptor antagonists in congestive heart failure. Drugs (2001) 61:1387–1393.
   PubMed Web of Science ®Google Scholar
• LUCAS DG Jr, PATTERSON T, HENDRICK JW et al: Effects of adenosine receptor subtype Al on ventricular and renal function. J. Cardiovasc. Pharmacol (2001) 38:618–624.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB SS, SKETTINO SL, WOLFF A et al: Effects of BG9719 (CVT-124), an Al-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. J. Am. Coll. Cardiol. (2000) 35:56–59.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB SS, BRATER DC, THOMAS I et al: BG9719 (CVT-124), an Al adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation (2002) 105:1348–1353.
   PubMed Web of Science ®Google Scholar
• MILLS RM, HOBBS RE, YOUNG JB: BNP for heart failure: role of nesiritide in cardiovascular therapeutics. Congest. Heart Fail (2002) 8:270–273.
   PubMedGoogle Scholar
• PUBLICATION COMMITTEE FOR THE VMAC INVESTIGATORS (VASODILATATION IN THE MANAGEMENT OF ACUTE CHF): Intravenous nesiritide versus nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA (2002) 287:1531–1540.
   PubMed Web of Science ®Google Scholar
• BURGER AJ, ELKAYAM U, NEIBAUR MT: Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Am. .1 Cardiol (2001) 88:35–39.
   PubMed Web of Science ®Google Scholar
• SACKNER-BERNSTEIN J, KOWALSKI M, FOX M: Is there risk associated with the use of nesiritide for acute heart failure? .1. Am. Coll Cardiol. (2003) 41:161A (Abstract 1085–70).
   Google Scholar
• POOLE-WILSON PA, SWEDBERG K, CLELAND JGF et al.: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet (2003) 362:7–13.
   PubMed Web of Science ®Google Scholar
• POOLE-WILSON PA: Clinical trials update II (Heart Failure) - the Carvedilol Or Metoprolol European Trial (COMET).
   Google Scholar
• European Socieg, of Cardiology Congress 2003, Vienna, Austria (2003).
   Google Scholar
• MERIT-HF INVESTIGATORS: Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet (1999) 353:2001–2007.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED]: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (2001) 353:9–13.
   Web of Science ®Google Scholar
• OTTERSTAD JE, FORD I: The effect ofcarvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction. How do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with previous beta-blocker trials? Eur. J. Heart Fail. (2002) 4:501–506.
   Google Scholar
• McNEELY W, GOA K: Nebivolol in themanagement of essential hypertension. A review. Drugs (1999) 57:633–651.
   Google Scholar
• SHIBATA MC, FLATHER MD, BOHM M et al: Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS). Rationale and design. Int. J. Cardiol. (2002) 86:77–85.
   PubMed Web of Science ®Google Scholar
• RAJFER SI, DAVIS FR: Role of dopaminereceptors and the utility of dopamine agonists in heart failure. Circulation (1990) 82:197–1102.
   Google Scholar
• HAMPTON JR, VAN VELDHUISEN DJ,KLEBER FX et al.: Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet (1997) 349:971–977.
   Google Scholar
• TJEERDSMA G, VAN WIJK LM, MOLHOEK GP et al: Autonomic and hemodynamic effects of a new selective dopamine agonist, CHF1035, in patients with chronic heart failure. Cardiovasc. Drugs Ther. (2001) 15:139–145.
   PubMed Web of Science ®Google Scholar
• FIGGITT DP, GILLIES PS, GOA KL: Levosimendan. Drugs (2001) 61:613–627.
   PubMed Web of Science ®Google Scholar
• CLELAND JG, McGOWAN J: Levosimendan: a new era for inodilator therapy for heart failure? Curr. Opin. Cardiol. (2002) 17:257–265.
   PubMed Web of Science ®Google Scholar
• KIVIKKO M, LECHTONEN L, COLUCCI WS: Sustained hemodynamic effects of levosimendan. Circulation (2003) 107:81–86.
   PubMed Web of Science ®Google Scholar
• AJIRO Y, HAGIWARA N, KATSUBE Y, SPERELAKIS N, KASANUKI H: Levosimendan increases L-type Ca(2÷) current via phosphodiesterase-3 inhibition in human cardiac myocytes. Eur. Pharmacol. (2002) 435:27–33.
   PubMed Web of Science ®Google Scholar
• FOLLATH F, CLELAND JGF, JUST H: Efficacy and safety of intravenous levosimendan, a novel calcium sensitiser, in severe low output failure. Lancet (2002).
   Google Scholar
• MOISEYEV VS, PODER P, ANDREJEVS N et al.: Randomized study on safety and effectiveness of levosimendan in patients with left ventricular heart failure after an acute myocardial infarction (the RUSSLAN study). Eur. Heart J. (2002) 23(18):1422–1432.
   PubMed Web of Science ®Google Scholar
• MANN DL: Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ. Res. (2002) 91:988–998.
   PubMed Web of Science ®Google Scholar
• KRUM H: Tumor necrosis factor-a blockade as a therapeutic strategy in heart failure (RENEWAL and ATTACH): unsuccessful, to be specific. J. Card. Fail. (2002) 8:365–368.
   PubMed Web of Science ®Google Scholar
• TORRE-AMIONE G: Immune modulation therapy reduces death and hospitalization in class III/IV heart failure patients: results of a randomized clinical trial. American Heart Association 75th Annual Scientific Sessions, Chicago, IL, USA. Circulation (2002) 106:11-469 (Abstract 2324).
   Google Scholar
• NODE K, FUJITA M, KITAKAZE M et al.: Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation (2003) 108:839–843.
   PubMed Web of Science ®Google Scholar
• FARQUHARSON CA, BUTLER R, HILL A, BELCH JJ, STRUTHERS AD: Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation (2002) 106:221–226.
   PubMed Web of Science ®Google Scholar
• CAPPOLA TP, KASS DA, NELSON GS et al.: Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation (2001) 104:2407–2411.
   PubMed Web of Science ®Google Scholar
• VASAN S, FOILES PG, FOUNDS HW: Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links. Expert Opin. Investig. Drugs (2001) 10:1977–1987.
   PubMed Web of Science ®Google Scholar
• KASS DA, SHARPRIO EP, KAWAGUCHI M et al.: Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation (2001) 104:1464–1470.
   PubMed Web of Science ®Google Scholar
• OLDFIELD MD, BACH LA, FORBES JM etaL: Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). Clin. Invest. (2001) 108:1853–1863.
   Google Scholar
• SCHOFIELD RS, HILL JA: The use of ranolazine in cardiovascular disease. Expert Opin. Investig. Drugs (2002) 11:117–123.
   PubMed Web of Science ®Google Scholar
• CHANDLER MP, STANLEY WC, MORITA H et al: Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure. Circ. Res. (2002) 91:278–280.
   PubMed Web of Science ®Google Scholar
• PEPINE CJ, WOLFF AA: A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group. Am. Cardiol. (1999) 84:46–50.
   PubMed Web of Science ®Google Scholar
• RUPP H, ZARAIN-HERZBERG A, MAISCH B: The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Herz (2002) 27:621–636.
   PubMed Web of Science ®Google Scholar
• SABBAH HN, CHANDLER MP, MISHIMA T et al.: Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J. Card. Fah. (2002) 8:416–422.
   PubMed Web of Science ®Google Scholar
• BRISTOW M: Etomoxir: a new approachto treatment of chronic heart failure. Lancet (2000) 356:1621–1622.
   PubMed Web of Science ®Google Scholar
• SCHMIDT-SCHWEDA S, HOLUBARSCH C: First clinical trial with etomoxir in patients with chronic congestive heart failure. Clia Sci. aoncli (2000) 99:27–35.
   PubMed Web of Science ®Google Scholar
• RUPP H, JACOB R: Metabolically-modulated growth and phenotype of the rat heart. Eur. Heart J. (1992) 13(Suppl. D):56–61.
   Google Scholar
• NIKOLAIDIS LA, SOKOS GG, MANKAD SV et al: GLP-1 improves clinical and functional performance in patients with advanced heart failure. Heart Failure Society of America 7th Annual Scientific Meeting, Las Vegas, NV, USA. Card. Fah. (2003) 9:S9.
   Google Scholar
• HAMILTON MA, STEVENSON LW, FORANOW GC et al.: Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure. Am. J. Cardiol. (1998) 81:443–447.
   PubMed Web of Science ®Google Scholar
• PENNOCK GD, RAVA TE, BAHL JJ, GOLDMAN S, MORKIN E: Combination treatment with captopril and the thyroid hormone analogue, 3,5-diiodothyropropionic acid. A new approach to improve left ventricular performance in heart failure. Circ. J. (1993) 88:1289–1298.
   Google Scholar
• MORKIN E, PENNOCK GD, SPOONER PH et al: Pilot studies on the use of 3,5-diiodothyropropionic acid, a thyroid hormone analog, in the treatment of congestive heart failure. Cardiology (2002) 97:218–225.
   PubMed Web of Science ®Google Scholar
• FAZIO S, SABATINI D, CAPALDO B et al.: A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl. I Med. (1996) 334:809–814.
   PubMed Web of Science ®Google Scholar
• JENKINS RC, ROSS RJ: The growth hormone IGF-I axis in dilated cardiomyopathy. Clin. Endocrinol. (Oxf.) (1999) 50:415–416.
   PubMed Web of Science ®Google Scholar
• OSTEZIEL KJ, STROHM 0, SCHULER J et al.: Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet (1998) 351:1233–1237.
   Google Scholar
• SILVERBERG DS, WEXLER D, IAINA A:The importance of anemia and its correlation in the management of severe congestive heart failure. Eur..I. Heart Fail. (2002) 4:681–686.
   PubMed Web of Science ®Google Scholar
• DONNE RL, FOLEY RN: Anaemia management and cardiomyopathy in renal failure. Nephrol. Dial. Transplant. (2002) 17:37–40.
   PubMed Web of Science ®Google Scholar
• SILVERBERG DS, WEXLER D, BLUM M et al.: The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J. Am. Coll Cardiol. (2000) 35:1737–1744.
   PubMed Web of Science ®Google Scholar
• SILVERBERG DS, WEXLER D, SHEPS D et al: The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. j Am. Coll. Cardiol (2001) 37:1775–1780.
   PubMed Web of Science ®Google Scholar
• PERROT A, OSTERZIEL KJ, BECK M, DIETZ R, KAMPMANN C: Fabry disease: focus on cardiac manifestations and molecular mechanisms. Herz (2002) 27:699–702.
   PubMed Web of Science ®Google Scholar
• MACDERMOT KD, HOLMES A, MINERS AH: Anderson-Fabry disease: clinical manifestations and impact on disease in a cohort of 98 hemizygote males. J. Med. Genet. (2001) 38:750–760.
   PubMed Web of Science ®Google Scholar
• ENG CM, GUFFON N, WILCOX WR: Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in FabrYs disease. N Engl. I Med. (2001) 345:9–16.
   PubMed Web of Science ®Google Scholar
• SCHIFFMANN R, KOPP JB, AUSTIN HA: Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA (2001) 285:2743–2749.
   PubMed Web of Science ®Google Scholar
• YUSUF S, PITT B: A lifetime of prevention: the case of heart failure. Circulation (2002) 106:2997–2998.
   PubMed Web of Science ®Google Scholar
• YUSUF S, SLEIGHT P, POGUE J et al: Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl. I Med. (2000) 342:145–153.
   PubMed Web of Science ®Google Scholar
• (NO AUTHORS LISTED): Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet (2000) 355:253–259.
   Google Scholar
• DAHLOF B, DEVEREUX RB, KJELDSEN SE et al: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 359:995–1003.
   PubMed Web of Science ®Google Scholar
• FOX KM: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet (2003) 362:782–788.
   PubMed Web of Science ®Google Scholar
• HUNT SA, BAKER DW, CHIN MH et al.: ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Am. Coll. Cardiol. (2001) 38:2101–2113.
   Google Scholar